Healthcare Industry News:  arrhythmia 

Devices Cardiology Regulatory

 News Release - June 8, 2011

Advanced Cardiac Therapeutics Announces CE Mark Clearance For Innovative Catheter System for the Treatment of Atrial Arrhythmias

World’s First Temperature-Sensing Saline Irrigated Ablation Catheter Enables Lesion Control, Is Designed to Improve Patient Outcomes

LAGUNA BEACH, Calif.--(Healthcare Sales & Marketing Network)-- Advanced Cardiac Therapeutics, Inc., a developer of innovative temperature-sensing cardiac ablation systems, today announced that the company has received CE Mark (Conformité Européenne) clearance for its TEMPASURE™ cardiac ablation catheter. The TEMPASURE system is the world’s first RF cardiac ablation catheter to offer both saline irrigation and temperature-sensing technology.

The TEMPASURE system is designed to result in better outcomes for patients by reducing overall procedure time and increasing therapeutic effectiveness, while avoiding rare but serious adverse events that can occur with current technologies. The system’s novel passive sensing microwave radiometry technology allows the electrophysiologist to measure the temperature of cardiac tissue during the ablation procedure, providing real-time information that enables proper energy delivery and lesion control. This technology is designed to allow, for the first time, safe and effective automatic RF power titration or “Temperature Mode” irrigated ablation.

“We are very pleased that the TEMPASURE temperature-sensing ablation catheter is now cleared for use in countries that recognize CE Mark,” said Peter van der Sluis, the company’s CEO. “We look forward to bringing the TEMPASURE system to patients and physicians in Europe later this year.”

“For more than 20 years, the temperature sensing and energy titration in ‘temperature mode’ in non-irrigated traditional RF catheters have been successful and proven tools to safely guide right-sided ablation procedures and optimize outcomes,” said Vivek Y. Reddy M.D., The Helmsley Trust Professor of Medicine and director, Cardiac arrhythmia Service at the Mount Sinai Medical Center in New York. “However, the lack of temperature sensing on the proven irrigated RF catheter platform has limited outcomes in left-sided procedures. I am excited to see ACT’s new radiometry technology make available two new features for the first time in left-sided ablation procedures. The company’s technology offers real-time safe temperature control during ablations and in the near term promises automatic titration of RF power to create consistent, deep and wide lesions.”

About Cardiac arrhythmias

Cardiac arrhythmias occur when the electrical impulses in the heart don't work properly, causing the heart to beat too fast, too slowly or irregularly. Atrial fibrillation and atrial flutter are fast cardiac arrhythmias that can be life-threatening.

About Cardiac Catheter Ablation

Cardiac catheter ablation procedures are used to treat a variety of cardiac arrhythmias including atrial fibrillation and atrial flutter. The procedures involve advancing a catheter into the heart and selectively ablating certain areas of tissue in order to prevent the spread of electrical signals that give rise to the arrhythmia. The temperature of the tissue during ablation is critical – lower temperatures are ineffective, and temperatures that are too high can result in dangerous over-heating. Saline irrigation ensures that lesions are created safely and are effective deeper inside the cardiac tissue. However, the inclusion of irrigation negates the effectiveness of conventional thermometry.

About the TEMPASURE Cardiac Ablation Catheter

ACT's technology enables, for the first time, measurement of tissue temperature with a saline-irrigated RF catheter. The TEMPASURE cardiac ablation catheter continuously measures temperature at three millimeters depth below the heart wall surface using VERITAS™ Technology, a proprietary microwave radiometry system. The TEMPASURE system is designed to improve patient outcomes by providing electrophysiologists with real-time validation information and greater control in lesion creation.

About Advanced Cardiac Therapeutics

Headquartered in Laguna Beach, Calif., privately held Advanced Cardiac Therapeutics, Inc. specializes in advanced irrigated cardiac catheter ablation systems with proprietary temperature-sensing technology for the treatment of patients with cardiac arrhythmias. For more information visit www.actmed.net.


Source: Advanced Cardiac Therapeutics

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.